WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation

Srdan Verstovsek, Taghi Manshouri, Alfonso Quintás-Cardama, David Harris, Jorge Cortes, Francis J. Giles, Hagop Kantarjian, Waldemar Priebe, Zeev Estrov

Research output: Contribution to journalArticle

Abstract

Purpose: The discovery of an activating somatic mutation in codon 617 of the gene encoding the Janus kinase (JAK)-2 (JAK2 V617F) in patients with myeloproliferative disorders has opened new avenues for the development of targeted therapies for these malignancies. However, no effective JAK2 inhibitors are currently available for clinical use. Experimental Design: We investigated the activity of (E)-3(6-bromopyridin-2-yl)-2-cyano-N-(S0-1phenylethyl)acrylamide (WP1066), a novel analogue of the JAK2 inhibitor AG490, in JAK2 V617F-positive erythroleukemia HEL cells and in blood cells from patients with polycythemia vera. Results: We found that WP1066 significantly inhibited JAK2 and its downstream signal transducer and activator of transcription-3, signal transducer and activator of transcription-5, and extracellular signal-regulated kinase-1/2 pathways in a dose- and time-dependent manner. As a result, WP1066 concentrations in the low micromolar range induced time- and dose-dependent antiproliferative and proapoptotic effects in HEL cells. As expected, WP1066 inhibited the proliferation of peripheral blood hematopoietic progenitors of patients with polycythemia vera carrying the JAK2 V617F mutation in a dose-dependent manner. Conclusions: Our data suggest that WP1066 is active both in vitro and ex vivo and should be further developed for the treatment of neoplasms expressing the JAK2 V617F mutation.

Original languageEnglish (US)
Pages (from-to)788-796
Number of pages9
JournalClinical Cancer Research
Volume14
Issue number3
DOIs
StatePublished - Feb 1 2008
Externally publishedYes

Fingerprint

Erythroid Cells
Apoptosis
Mutation
Polycythemia Vera
STAT5 Transcription Factor
Janus Kinase 2
STAT3 Transcription Factor
Myeloproliferative Disorders
Leukemia, Erythroblastic, Acute
Mitogen-Activated Protein Kinase 3
Acrylamide
Mitogen-Activated Protein Kinase 1
Codon
Blood Cells
Neoplasms
Research Design
WP1066
Therapeutics
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. / Verstovsek, Srdan; Manshouri, Taghi; Quintás-Cardama, Alfonso; Harris, David; Cortes, Jorge; Giles, Francis J.; Kantarjian, Hagop; Priebe, Waldemar; Estrov, Zeev.

In: Clinical Cancer Research, Vol. 14, No. 3, 01.02.2008, p. 788-796.

Research output: Contribution to journalArticle

Verstovsek, S, Manshouri, T, Quintás-Cardama, A, Harris, D, Cortes, J, Giles, FJ, Kantarjian, H, Priebe, W & Estrov, Z 2008, 'WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation', Clinical Cancer Research, vol. 14, no. 3, pp. 788-796. https://doi.org/10.1158/1078-0432.CCR-07-0524
Verstovsek, Srdan ; Manshouri, Taghi ; Quintás-Cardama, Alfonso ; Harris, David ; Cortes, Jorge ; Giles, Francis J. ; Kantarjian, Hagop ; Priebe, Waldemar ; Estrov, Zeev. / WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 3. pp. 788-796.
@article{710d2c3f7b304db292dcc20ad3dbdbe6,
title = "WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation",
abstract = "Purpose: The discovery of an activating somatic mutation in codon 617 of the gene encoding the Janus kinase (JAK)-2 (JAK2 V617F) in patients with myeloproliferative disorders has opened new avenues for the development of targeted therapies for these malignancies. However, no effective JAK2 inhibitors are currently available for clinical use. Experimental Design: We investigated the activity of (E)-3(6-bromopyridin-2-yl)-2-cyano-N-(S0-1phenylethyl)acrylamide (WP1066), a novel analogue of the JAK2 inhibitor AG490, in JAK2 V617F-positive erythroleukemia HEL cells and in blood cells from patients with polycythemia vera. Results: We found that WP1066 significantly inhibited JAK2 and its downstream signal transducer and activator of transcription-3, signal transducer and activator of transcription-5, and extracellular signal-regulated kinase-1/2 pathways in a dose- and time-dependent manner. As a result, WP1066 concentrations in the low micromolar range induced time- and dose-dependent antiproliferative and proapoptotic effects in HEL cells. As expected, WP1066 inhibited the proliferation of peripheral blood hematopoietic progenitors of patients with polycythemia vera carrying the JAK2 V617F mutation in a dose-dependent manner. Conclusions: Our data suggest that WP1066 is active both in vitro and ex vivo and should be further developed for the treatment of neoplasms expressing the JAK2 V617F mutation.",
author = "Srdan Verstovsek and Taghi Manshouri and Alfonso Quint{\'a}s-Cardama and David Harris and Jorge Cortes and Giles, {Francis J.} and Hagop Kantarjian and Waldemar Priebe and Zeev Estrov",
year = "2008",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-07-0524",
language = "English (US)",
volume = "14",
pages = "788--796",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation

AU - Verstovsek, Srdan

AU - Manshouri, Taghi

AU - Quintás-Cardama, Alfonso

AU - Harris, David

AU - Cortes, Jorge

AU - Giles, Francis J.

AU - Kantarjian, Hagop

AU - Priebe, Waldemar

AU - Estrov, Zeev

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Purpose: The discovery of an activating somatic mutation in codon 617 of the gene encoding the Janus kinase (JAK)-2 (JAK2 V617F) in patients with myeloproliferative disorders has opened new avenues for the development of targeted therapies for these malignancies. However, no effective JAK2 inhibitors are currently available for clinical use. Experimental Design: We investigated the activity of (E)-3(6-bromopyridin-2-yl)-2-cyano-N-(S0-1phenylethyl)acrylamide (WP1066), a novel analogue of the JAK2 inhibitor AG490, in JAK2 V617F-positive erythroleukemia HEL cells and in blood cells from patients with polycythemia vera. Results: We found that WP1066 significantly inhibited JAK2 and its downstream signal transducer and activator of transcription-3, signal transducer and activator of transcription-5, and extracellular signal-regulated kinase-1/2 pathways in a dose- and time-dependent manner. As a result, WP1066 concentrations in the low micromolar range induced time- and dose-dependent antiproliferative and proapoptotic effects in HEL cells. As expected, WP1066 inhibited the proliferation of peripheral blood hematopoietic progenitors of patients with polycythemia vera carrying the JAK2 V617F mutation in a dose-dependent manner. Conclusions: Our data suggest that WP1066 is active both in vitro and ex vivo and should be further developed for the treatment of neoplasms expressing the JAK2 V617F mutation.

AB - Purpose: The discovery of an activating somatic mutation in codon 617 of the gene encoding the Janus kinase (JAK)-2 (JAK2 V617F) in patients with myeloproliferative disorders has opened new avenues for the development of targeted therapies for these malignancies. However, no effective JAK2 inhibitors are currently available for clinical use. Experimental Design: We investigated the activity of (E)-3(6-bromopyridin-2-yl)-2-cyano-N-(S0-1phenylethyl)acrylamide (WP1066), a novel analogue of the JAK2 inhibitor AG490, in JAK2 V617F-positive erythroleukemia HEL cells and in blood cells from patients with polycythemia vera. Results: We found that WP1066 significantly inhibited JAK2 and its downstream signal transducer and activator of transcription-3, signal transducer and activator of transcription-5, and extracellular signal-regulated kinase-1/2 pathways in a dose- and time-dependent manner. As a result, WP1066 concentrations in the low micromolar range induced time- and dose-dependent antiproliferative and proapoptotic effects in HEL cells. As expected, WP1066 inhibited the proliferation of peripheral blood hematopoietic progenitors of patients with polycythemia vera carrying the JAK2 V617F mutation in a dose-dependent manner. Conclusions: Our data suggest that WP1066 is active both in vitro and ex vivo and should be further developed for the treatment of neoplasms expressing the JAK2 V617F mutation.

UR - http://www.scopus.com/inward/record.url?scp=38949086558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949086558&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0524

DO - 10.1158/1078-0432.CCR-07-0524

M3 - Article

C2 - 18245540

AN - SCOPUS:38949086558

VL - 14

SP - 788

EP - 796

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -